Two targets are better than one. Promising combination therapy to treat breast cancer

Cancer Biol Ther. 2005 Nov;4(11):1190-1. doi: 10.4161/cbt.4.11.2335. Epub 2005 Nov 18.
No abstract available

Publication types

  • Research Support, N.I.H., Extramural
  • Comment

MeSH terms

  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / therapeutic use*
  • Benzamides / pharmacology
  • Benzamides / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / enzymology
  • Breast Neoplasms / genetics
  • Breast Neoplasms / metabolism
  • Cell Line, Tumor
  • Drug Therapy, Combination*
  • Enzyme Inhibitors / pharmacology
  • ErbB Receptors / drug effects
  • Female
  • Humans
  • Mitogen-Activated Protein Kinase 1 / antagonists & inhibitors
  • Mitogen-Activated Protein Kinase 3 / antagonists & inhibitors
  • Mutation
  • Protein Kinase Inhibitors / pharmacology
  • Receptor, ErbB-2 / drug effects
  • Signal Transduction
  • Staurosporine / analogs & derivatives*
  • Staurosporine / pharmacology
  • Staurosporine / therapeutic use

Substances

  • 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide
  • Antineoplastic Agents
  • Benzamides
  • Enzyme Inhibitors
  • Protein Kinase Inhibitors
  • 7-hydroxystaurosporine
  • ErbB Receptors
  • Receptor, ErbB-2
  • Mitogen-Activated Protein Kinase 1
  • Mitogen-Activated Protein Kinase 3
  • Staurosporine